Treating TED: More Than Meets the Eye (CME Monograph)

To obtain credit for this course after reading this supplement to Review of Ophthalmology, click Take Course (above or to the right) and complete the Posttest and Evaluation. A certificate will be instantly available.


Activity Description and Purpose

This educational activity aims to equip oculoplastic surgeons and ophthalmologists with advanced knowledge of the diagnosis, individualized treatment planning, and management of thyroid eye disease (TED), highlighting the importance of a collaborative, multidisciplinary care team. Through engaging content delivered by esteemed experts, participants will explore TED diagnostic criteria, the latest clinical data for creating personalized treatment plans, and effective strategies for managing adverse effects such as hyperglycemia and hearing loss associated with insulin-like growth factor-1 receptor antagonists. The educational activity integrates didactics, clinical case studies, and discussion panels, designed to reinforce learning objectives and encourage the application of knowledge in clinical settings. The desired results of this activity are to improve clinicians’ ability to accurately diagnose TED, optimally integrate therapies for TED according to clinical data, identify and manage treatment-related adverse events, and incorporate strategies for fostering multidisciplinary collaboration to ensure the best possible outcomes for patients living with this disease.

Target Audience

This educational activity is intended for ophthalmologists and oculoplastic surgeons.

Learning Objectives

After completing this activity, participants will be better able to:

  • Review diagnostic criteria that are critical in identifying patients with thyroid eye disease
  • Create individualized treatment plans for patients with thyroid eye disease according to the latest clinical data
  • Develop strategies for mitigating hyperglycemia and hearing loss in patients with thyroid eye disease receiving insulin-like growth factor 1 receptor antagonists
  • Outline the roles and responsibilities of the multidisciplinary care team in thyroid eye disease management
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
Course expires: 


Andrew G. Lee, MD (Chair)
Herb and Jean Lyman Centennial Chair in Ophthalmology
Department of Ophthalmology
Blanton Eye Institute
Professor of Ophthalmology, Neurology, and Neurosurgery
Academic Institute
Full Clinical Member
Research Institute
Houston Methodist
Weill Cornell Medical College
Houston, Texas

Eugene L. Alford, MD, FACS
Associate Professor of Otolaryngology and Plastic Surgery
Academic Institute Houston Methodist Hospital
Weill Medical College of Cornell University
Adjunct Professor
Texas A&M Intercollegiate College of Medicine (EnMed)
Houston, Texas

Victor J. Bernet, MD, FACE, FACP
Endocrinology, Diabetes and Metabolism Fellowship Program
Professor of Medicine
Mayo Clinic College of Medicine and Science
Mayo Clinic
Jacksonville, Florida
Wendy W. Lee, MD, MS
Professor of Clinical Ophthalmology and Dermatology
Oculofacial Plastic & Reconstructive Surgery, Orbit, and Oncology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, Florida
Joseph Sowka, OD, FAAO
Center for Sight
Venice, Florida
Prem S. Subramanian, MD, PhD
Chief, Neuro-Ophthalmology
Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology
Vice Chair for Academic Affairs, Ophthalmology
Professor in Ophthalmology, Neurology, and Neurosurgery
Sue Anschutz-Rodgers University of Colorado Eye Center
University of Colorado School of Medicine
Aurora, Colorado

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.


Eugene Alford, MD, has no relevant commercial relationships to disclose.

Victor Bernet, MD, has no relevant commercial relationships to disclose.

Andrew G. Lee, MD, is a consultant for Alexion Pharmaceuticals, Inc, AstraZeneca, Bristol-Myers Squibb, Stoke Therapeutics and Viridian Therapeutics, Inc; and is on the speakers bureau for Amgen Inc.

Wendy W. Lee, MD, MS, is a consultant for AbbVie Inc, Amgen Inc, Mallinckrodt*,  Novabay Pharmaceuticals, Inc, Revance Therapeutics, Inc, RVL Pharmaceuticals, Inc*, and Tarsus Pharmaceuticals, Inc; and is a contracted researcher for Viridian Therapeutics, Inc.

Joseph Sowka, OD, is on the speakers bureau for Bausch & Lomb Incorporated.

Prem S. Subramanian, MD, PhD, is a consultant for ACELYRIN, Inc; is an advisory board member of Amgen Inc, GenSight Biologics, Kriya Therapeutics, and Viridian Therapeutics, Inc; and is a contracted researcher for Amgen Inc, Immunovant, Inc, Invex Therapeutics*, Neurophth Therapeutics, Tourmaline Bio, Inc, and Viridian Therapeutics, Inc.

Peer Reviewer

Hadi Kaakour, MD, was formerly an advisory board member of Alimera Sciences*.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

* The financial relationship existed during the past 24 months but has now ended.

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Amgen Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Amgen Inc, or Review of Ophthalmology.

This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 313

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CME information for this activity.